Anti Inflammatory News and Research

RSS

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Bbiotechnology company NEUROKIN, dedicated to the development of neuroprotective drugs to treat acute neurological diseases, announces today that the European Patent Office (EPO) has granted patent EP 1998778 protecting the use of NK-102, its most advanced drug candidate. This first European award constitutes an important milestone for NEUROKIN. An application for registration is under way in Brazil, Canada, China, USA and Japan.

29 Sep 2010

Sanford-Burnham receives five-year core grant renewal from NCI

The Cancer Center at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has received a five-year core grant renewal from the National Cancer Institute (NCI).

29 Sep 2010

Chelsea Therapeutics announces $35 million in shares in registered public offering

Chelsea Therapeutics International, Ltd. announced today its intention, subject to market and other conditions, to offer $35 million in shares of its common stock in a registered public offering pursuant to its existing shelf registration statement.

29 Sep 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

ISTA Pharmaceuticals, Inc. today highlighted results from the Company's REMURA (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.

27 Sep 2010

Technologic innovation — Telephones! — could save health system money

Health-coaching more patients over the phone could help save the system money according to a study published Wednesday in the New England Journal of Medicine and noticed by the Wall Street Journal's Health Blog. "Typically this kind of care management, as it's called, is offered to people who have trouble managing their chronic conditions or who are facing a big treatment decision — such as surgery or medical management for lower back pain.

24 Sep 2010

Abbott, Reata enter agreement to commercialize bardoxolone drug for CKD

Abbott and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD).

24 Sep 2010

Interleukin Genetics announces clinical study data on osteoarthritis progression

Interleukin Genetics, Inc. and the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill announced today findings from a large clinical study to evaluate the role of genetic factors in osteoarthritis progression which showed patients with radiographic evidence of knee osteoarthritis who inherited a specific pattern of genetic variations in the interleukin-1 receptor antagonist (IL-1Ra) gene were almost twice as likely to progress to severe disease as other patients.

23 Sep 2010

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.

23 Sep 2010

Study links progressive osteoarthritis to IL-1Ra gene variations

Scientists from University of North Carolina at Chapel Hill School of Medicine and Interleukin Genetics, Inc. announced today findings from a large clinical study to evaluate the role played by genetic factors in the worsening of osteoarthritis.

22 Sep 2010

Sun Pharma completes acquisition of controlling stake in Taro

Sun Pharmaceutical Industries Ltd. today announced that it has completed the acquisition of a controlling stake in Taro Pharmaceutical Industries Ltd. pursuant to the Option Agreement entered into in 2007 with Taro's controlling shareholders led by Taro's Chairman, Dr. Barrie Levitt.

22 Sep 2010

New genes associated with osteoarthritis progression

21 Sep 2010

ProtAffin presents impressive efficacy data for PA401 in COPD

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. This conference is the largest gathering of scientists and clinicians in the respiratory community in the world. The Oral Presentation will be made in the session "Pre-clinical models of airways disease".

21 Sep 2010

NIMU, NMRC sign CRADA agreement

Non-Invasive Monitoring Systems, Inc. announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC) in Silver Springs, MD to evaluate the benefit of Exer-Rest for patients with traumatic brain injury (TBI).

21 Sep 2010

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.

20 Sep 2010

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Harbor BioSciences, Inc. today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286). The patent claims cover compounds including Triolex and formulations that contain the drug or the other claimed compounds.

20 Sep 2010

Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint

Chelsea Therapeutics International, Ltd. announced that preliminary analyses of its Phase III NORTHERA™ Study 301 met its primary endpoint. Treatment with Northera provided clinically meaningful and statistically significant improvement.

20 Sep 2010

Lisofylline drug effective for Type 2 diabetes

Australian scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes.

20 Sep 2010

URB937 drug boosts natural painkiller level: Study

A new study has shown how a novel compound boosts levels of a natural painkiller at the site of an injury. The ground-breaking study published today in Nature Neuroscience shows how the potential drug URB937 acts in peripheral tissue and may have the potential to relieve pain without the side effects associated with many current painkillers that act centrally on the nervous system.

20 Sep 2010

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.

17 Sep 2010

Anti Inflammatory News and Research

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Sanford-Burnham receives five-year core grant renewal from NCI

Chelsea Therapeutics announces $35 million in shares in registered public offering

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

Technologic innovation — Telephones! — could save health system money

Abbott, Reata enter agreement to commercialize bardoxolone drug for CKD

Interleukin Genetics announces clinical study data on osteoarthritis progression

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

Study links progressive osteoarthritis to IL-1Ra gene variations

Sun Pharma completes acquisition of controlling stake in Taro

New genes associated with osteoarthritis progression

ProtAffin presents impressive efficacy data for PA401 in COPD

NIMU, NMRC sign CRADA agreement

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Chelsea Therapeutics' Phase III NORTHERA Study 301 meets primary endpoint

Lisofylline drug effective for Type 2 diabetes

URB937 drug boosts natural painkiller level: Study

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News